A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse

Trial Profile

A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin; Pegfilgrastim
  • Indications Leiomyosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2014 A results of this study assessing the association between febrile neutropenia and skeletal muscle mass (SMM) and skeletal muscle densities (SMD) presented at the 2014 Annual Meeting of the ASCO, according to a PharmaMar media release.
    • 17 May 2013 First results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2013, according to a PharmaMar media release.
    • 20 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top